Ferring Pharmaceuticals Announces Immediate Availability Of Degarelix For The Treatment Of Advanced Prostate Cancer

News — By on April 14, 2009 at 12:46 pm

Ferring Pharmaceuticals, USA announced the U.S. commercial availability of degarelix for injection (trade name pending), a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. Degarelix is available for order through traditional and specialty pharmacy distributors. Degarelix provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth.(1-3) Clinical trials demonstrated that degarelix is effective in quickly reducing and sustaining castrate levels of testosterone.(2,3) Degarelix works differently than a luteinizing hormone-releasing hormone (LHRH) agonist by…

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback